Ribonucleic Acid News and Research

RSS

Study explores SARS-CoV-2 viremia kinetics

In a new study, researchers evaluated the kinetics of severe acute respiratory syndrome coronavirus-2 viremia.

14 Mar 2022

Study explores neutralization of SARS-CoV-2 Omicron variant by subunit vaccine boosters

A new study assessed the neutralization induced by subunit vaccine boosters specific for the SARS-CoV-2 Omicron variant of concern.

14 Mar 2022

Bioactive small molecules enhance CRISPR/Cas9 loss-of-function editing in human cells

Researchers demonstrate enhanced loss-of-function editing of CRISPR/Cas9 in human cells.

14 Mar 2022

Neutralizing activity of therapeutic antibodies against clinical strains of BA.1 and BA.2 sub-lineages of the Omicron variant

Researchers conducted an in vitro analysis to assess the efficacy of monoclonal antibodies against the SARS-CoV-2 Omicron BA.2 and BA.1 variants.

14 Mar 2022

Immunobridging study shows immunogenicity in adolescents receiving SARS-CoV-2 mRNA and inactivated vaccines

A recent study assessed the reactogenicity and immunogenicity induced by SARS-CoV-2 vaccines in adolescent individuals.

14 Mar 2022

Study indicates a 100 µg mRNA-1273 booster has acceptable safety and robust antibody response against SARS-CoV-2

A recent study assessed the safety and immunogenicity of mRNA-1273 booster vaccine against COVID-19.

11 Mar 2022

Updated results from ongoing study on the effect of a BNT162b2 booster dose on anti-SARS-CoV-2 antibodies

Researchers assessed the increase in Pfizer/BioNTech BNT162b2 vaccine efficacy on administering a homologous booster dose.

11 Mar 2022

Aminoglycoside antibiotic geneticin shows selective antiviral effect against SARS-CoV-2

Researchers elucidated antiviral activities of aminoglycoside geneticin against seven SARS-CoV-2 variants using different cell lines and respiratory tissues.

11 Mar 2022

Study finds chimeric mRNA induces potent and broadly acting neutralizing antibodies against SARS-CoV-2 variants

Researchers explored strategies to develop an mRNA-based COVID-19 vaccine that could elicit safer and wider protection against SARS-CoV-2 variants of concern.

10 Mar 2022

The trajectory of B-cell immunity six months after mRNA vaccination

Researchers assess SARS-CoV-2 antibodies in individuals vaccinated with a mRNA COVID-19 vaccine six months after receiving their second dose.

10 Mar 2022

Neutralizing antibody levels before symptomatic breakthrough infection in groups infected before and after Omicron emergence

Researchers assessed the levels of neutralizing antibodies in coronavirus disease patients.

9 Mar 2022

CRIPSR identifies cell-type-specific ACE2 modifiers

Researchers compile a list of candidate genes to identify the surface abundance of functional regulators of ACE2.

9 Mar 2022

Viral load reduction effectiveness of SARS-CoV-2 BNT162b2 mRNA booster vaccine wanes with time

In a new study, researchers conducted a retrospective analysis of the SAR-CoV-2 reverse transcriptase - quantitative polymerase chain reaction test measurements.

9 Mar 2022

Low SARS-CoV-2 diabetogenicity found in infected human pancreatic cells in vitro

Researchers assessed the diabetogenic potential of SARS-CoV-2 in a single cell in vitro analysis on the pancreatic islet cells.

9 Mar 2022

Intragenomic rearrangements help explain how SARS-CoV-2 variants arise

In a recent study posted to the bioRxiv* preprint server, researchers presented the intragenomic rearrangements of β-coronaviruses (CoVs), including severe acute respiratory syndrome CoV 2 (SARS-CoV-2).

9 Mar 2022

Lower exosome component 2 expression protects against clinical SARS-CoV-2 infection

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated that the lower expression of EXOSC2 human protein safeguards from clinical coronavirus disease 2019 (COVID-19). This protective effect was via the reduced EXOSC2 expression-associated suppression of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication.

9 Mar 2022

Ribonucleic Acid News and Research

Study explores SARS-CoV-2 viremia kinetics

Study explores neutralization of SARS-CoV-2 Omicron variant by subunit vaccine boosters

Bioactive small molecules enhance CRISPR/Cas9 loss-of-function editing in human cells

Neutralizing activity of therapeutic antibodies against clinical strains of BA.1 and BA.2 sub-lineages of the Omicron variant

Immunobridging study shows immunogenicity in adolescents receiving SARS-CoV-2 mRNA and inactivated vaccines

Study indicates a 100 µg mRNA-1273 booster has acceptable safety and robust antibody response against SARS-CoV-2

Updated results from ongoing study on the effect of a BNT162b2 booster dose on anti-SARS-CoV-2 antibodies

Aminoglycoside antibiotic geneticin shows selective antiviral effect against SARS-CoV-2

Study finds chimeric mRNA induces potent and broadly acting neutralizing antibodies against SARS-CoV-2 variants

The trajectory of B-cell immunity six months after mRNA vaccination

Neutralizing antibody levels before symptomatic breakthrough infection in groups infected before and after Omicron emergence

CRIPSR identifies cell-type-specific ACE2 modifiers

Viral load reduction effectiveness of SARS-CoV-2 BNT162b2 mRNA booster vaccine wanes with time

Low SARS-CoV-2 diabetogenicity found in infected human pancreatic cells in vitro

Intragenomic rearrangements help explain how SARS-CoV-2 variants arise

Lower exosome component 2 expression protects against clinical SARS-CoV-2 infection

Assessment of oligonucleotides as COVID-19 treatment

A new view of SARS-CoV-2 genome structure

How will mutations change the SARS-CoV-2 spike protein in the future?

Current and future perspectives of mRNA technology

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News